Calcifediol Supplements Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 15.14 Billion |
| Market Size (2030) | USD 23.63 Billion |
| CAGR (2025 - 2030) | 9.31% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Calcifediol Supplements Market Analysis
The Calcifediol Supplements Market size is estimated at USD 15.14 billion in 2025, and is expected to reach USD 23.63 billion by 2030, at a CAGR of 9.31% during the forecast period (2025-2030).
Calcifediol Supplements are dietary supplements containing calcifediol, also known as 25-hydroxyvitamin D. Calcifediol is a pre-hormone produced in the liver by the hydroxylation of vitamin D3 (cholecalciferol) and is the primary circulating form of vitamin D in the bloodstream. The calcifediol supplements market is driven by the increasing prevalence of osteopenia and osteoporosis, increasing vitamin D deficiency, and advances in extended-release formulations during the forecast period.
The increasing prevalence of osteopenia and osteoporosis, particularly among the aging population, is a significant driver for the calcifediol supplements market. These conditions are major health concerns as they contribute to elevated risks of fractures, loss of autonomy, and increased mortality, resulting in substantial healthcare costs and a growing social burden.
For instance, according to an article published in the Journal of Medical Internet Research (JMIR) Public Health and Surveillance in April 2024, a comprehensive cross-sectional study involving 16,377 participants from the Chinese Han population highlighted the growing prevalence of osteopenia and osteoporosis. The study revealed that 40.5% of individuals had osteopenia and 7.93% had osteoporosis, with age-standardized prevalence rates of 27.32% and 3.51%, respectively. Women, particularly postmenopausal females, exhibited significantly higher rates of these conditions compared to men, with 48.55% of postmenopausal women experiencing osteopenia and 14.05% suffering from osteoporosis. Thus, the correlation between declining BMD and the increased prevalence of osteopenia and osteoporosis represents a significant force for market growth during the forecast period.
Furthermore, Vitamin D deficiency is a widespread concern among older people, significantly impacting their overall health and quality of life. For instance, according to a study published in the Indian Journal of Orthopaedics in March 2024, a systematic review and meta-analysis until January 2023 revealed alarmingly high global prevalence rates of vitamin D deficiency among the elderly. The study found 59.7% of elderly individuals had vitamin D levels below 20 ng/mL (50 nmol/L). Furthermore, a subset analysis showed a prevalence of 27.5% for levels between 20-30 ng/mL (50-75 nmol/L) and 16% for levels above 30 ng/mL (75 nmol/L) in an elderly population. These findings underscore the widespread nature of the deficiency, which affects over half of the elderly population globally. Such high prevalence rates necessitate targeted interventions to address the health risks associated with inadequate vitamin D levels. Thus, the calcifediol supplements market is poised for significant growth during the forecast period.
Additionally, according to the European Journal of Nutrition in March 2023, the Spanish Society for Bone Research and Mineral Metabolism (SEIOMM) has established specific dosage regimens for calcifediol supplements to address varying levels of vitamin D deficiency across different populations, significantly driving the market for the calcifediol supplements. For the general population with severe deficiency (serum 25(OH)D concentrations below 25 nmol/L), SEIOMM recommends an initial dose of 266 µg per week for five weeks, followed by a maintenance dose of 266 µg per month. In cases of insufficiency (serum 25(OH)D concentrations between 25 and 62.5 nmol/L), a monthly dose of 266 µg is advised. For individuals with osteoporosis or other risk factors, the guidelines suggest a more frequent dosage: 266 µg per week for five weeks, then every 3–4 weeks for severe deficiency (serum 25(OH)D concentrations below 25 nmol/L), and every 3–4 weeks for insufficiency (serum 25(OH)D concentrations between 25 and 75 nmol/L).
Thus, these tailored regimens emphasize the importance of addressing specific deficiency levels and risk factors, boosting the demand for calcifediol supplements. As healthcare providers increasingly adopt these evidence-based guidelines, the calcifediol supplements market is poised for growth, highlighting its crucial role in managing vitamin D deficiency and promoting bone health.
These factors will contribute to the growth of the calcifediol supplements market. However, the high regulatory and clinical uncertainties and alternative treatments restrain market growth.
Calcifediol Supplements Market Trends
Osteoporosis Segment is Expected to Witness Significant Growth Over the Forecast Period
Calcifediol supplements are vital in managing osteoporosis by effectively raising serum 25-hydroxyvitamin D levels, which are crucial for calcium absorption and bone mineralization.
The calcifediol supplements market has a high incidence of fractures among women over fifty due to minor falls or bumps. A recent International Osteoporosis Foundation survey in October 2023 highlights that nearly 43% of women reported fractures after minor incidents, with the highest rates observed in Japan, at 73.3%, and the United Kingdom, at 60.9%. These alarming statistics underscore the need for preventive measures, such as calcifediol supplementation, to strengthen bone health and prevent fractures.
These supplements offer a proactive approach to managing bone health, potentially reducing the incidence of fractures and the associated healthcare burden. Therefore, the growing adoption of calcifediol supplements will propel segmental growth in the upcoming years.
Moreover, the increasing prevalence of high bone fracture rates in Australia presents a substantial opportunity for the calcifediol supplements market. High fracture rates are another compelling driver for the calcifediol supplements market. For instance, according to the Healthy Bones Australia 2024 report, in 2023, an estimated 193,482 fractures were related to osteoporosis and osteopenia in Australia. This figure will rise by 34%, reaching 237,632 fractures by 2033. This alarming increase, with a predicted frequency of one fracture every 30 seconds by 2033, highlights the critical role of calcifediol in mitigating fracture risks through improved bone health.
Furthermore, vitamin D is crucial in bone health, particularly in postmenopausal women at increased risk of osteoporosis. For instance, according to a study published in the Journal of Bone and Mineral Research in January 2023, vitamin D status is typically measured through serum 25(OH)D levels, with concentrations above 20 ng/mL considered sufficient and above 30 ng/mL as optimal. Regulatory updates have expanded the indications for monthly calcifediol 0.266 mg, initially approved for short-term treatment, to now include long-term use and the prevention of vitamin D deficiency.
Also, the demonstrated potency and long-term efficacy of calcifediol in managing vitamin D levels, particularly in postmenopausal women with osteoporosis, position it as a critical driver in the calcifediol supplements market. As clinical evidence continues to underscore its benefits over traditional cholecalciferol, calcifediol's role in the osteoporosis segment will likely expand, thereby driving the market’s growth during the forecast period.
Hence, with the increasing prevalence of osteoporosis, high fracture rates, and rising adoption of calcifediol supplements in pre-risk osteoporosis women, the studied segment is expected to witness notable growth over the forecast period.
North America is Expected to Dominate the Calcifediol Supplements Market
The North America calcifediol supplements market is driven by several key factors, including the rising prevalence of chronic kidney disease (CKD) and the associated need to manage secondary hyperparathyroidism (SHPT) effectively. Growing awareness of the importance of maintaining optimal vitamin D levels to support bone health and prevent complications such as cardiovascular disease also contributes to market growth.
Further, the growing recognition of the widespread presence of active vitamin D receptors across various tissues has highlighted the extensive physiological roles of the vitamin D endocrine system (VDES). For instance, according to a study published in the Nutrients in November 2024, the Institute of Medicine (IOM) of the United States defines sufficient levels as above 20 ng/mL, and several scientific associations and experts advocate for a higher threshold of over 30 ng/mL. This recommendation is especially pertinent for bone health, critical in individuals with osteoporosis or those at elevated risk of vitamin D deficiency, such as older adults. Given that calcifediol, a pre-activated form of vitamin D can efficiently raise serum 25(OH)D levels, its use is increasingly considered beneficial for achieving and maintaining these higher thresholds.
Therefore, the growing consensus on the necessity of higher serum 25(OH)D levels, particularly in vulnerable populations, has propelled the demand for calcifediol supplements in the United States.
Additionally, a study published by Kidney and Blood Pressure Research in April 2024 highlighted that the American Society of Nephrology’s Kidney study comparing phase 3 clinical trials and real-world studies reveals consistent benefits of extended-release calcifediol (ERC) treatment for secondary hyperparathyroidism (SHPT). In phase 3 studies, ERC was shown to increase 25(OH)D levels and significantly lower PTH levels, with 97% of patients achieving 25(OH)D levels ≥30 ng/mL and 40% experiencing a ≥30% reduction in PTH. In the real-world study, despite lower up-titration rates, 70% of patients reached 25(OH)D levels ≥30 ng/mL, and 40% had a ≥30% reduction in PTH.
Thus, these findings demonstrate ERC's effectiveness in managing SHPT across different settings and patient populations, highlighting its role in early treatment to delay disease progression. The increasing awareness and adoption of ERC for SHPT management are significant drivers of the calcifediol supplements market in the United States.
Moreover, according to a study published in the Clinical Kidney Journal in July 2024, in a Canadian trial involving 119 participants with chronic kidney disease (CKD) stages 3b–4, patients were randomized to receive a placebo, calcifediol, or calcitriol. After six months, the calcifediol group exhibited a significant reduction in increased pulse wave velocity (PWV) compared to the placebo group, with a between-group difference of −2.1 m/s. The potential cardiovascular benefits of calcifediol in CKD patients remain a focal point for further research and clinical consideration. This growing body of evidence propels healthcare providers to consider calcifediol a valuable addition to CKD treatment regimens, fueling the expansion of the calcifediol supplements market in Canada.
Consequently, the increasing preference for extended-release formulations like calcifediol and emerging studies for calcifediol efficacy are set to propel the North American market for calcifediol supplements.
Calcifediol Supplements Industry Overview
The calcifediol supplements market is highly fragmented, with a diverse mix of players ranging from large global companies to smaller regional firms, each offering a wide array of products tailored to various consumer needs. To enhance their market position and extend their reach, key players are increasingly adopting strategic initiatives such as new product launches, partnerships, and collaborations. The major players in the market include Chemvon Biotechnology Co. Ltd., Haoyuan Chemexpress Co. Ltd., BOC Science, Pharmaffiliates, DSM-Firmenich, Carbogen AMCIS, Chemicea, Midas Pharma, ApexBio Technology, Nouveau Healthcare among others.
Calcifediol Supplements Market Leaders
-
DSM-Firmenich
-
Carbogen AMCIS
-
Chemicea
-
ApexBio Technology
-
Midas Pharma
- *Disclaimer: Major Players sorted in no particular order
Calcifediol Supplements Market News
- October 2024: Immunotec unveiled SunRay, a cutting-edge vitamin D supplement featuring rapid-acting calcifediol. This product addresses the growing demand for highly bioavailable vitamin D solutions, particularly for individuals with significant deficiencies or those requiring immediate improvements in serum vitamin D levels.
- May 2024: DSM-Firmenich introduced Ampli-D, a novel calcidiol monohydrate ingredient specifically designed to raise vitamin D levels in the blood efficiently. This innovative product leverages the enhanced bioavailability of calcidiol to provide rapid and sustained increases in serum vitamin D concentrations, addressing the critical need for effective supplementation among populations with deficiencies. Approved as a novel food by the European Commission, Ampli-D represents a significant advancement in the calcifediol supplementation market.
Calcifediol Supplements Industry Segmentation
The calcifediol supplements market involves producing and selling supplements containing calcifediol, a form of vitamin D used to manage vitamin D insufficiency and secondary hyperparathyroidism, particularly in patients with chronic kidney disease. These supplements help increase serum 25-hydroxyvitamin D levels and support bone and cardiovascular health.
The calcifediol supplements market is segmented into type, application, and geography. By type, the market is segmented into immediate-release calcifediol and extended-release calcifediol. By application, the market is segmented into vitamin D deficiency, osteoporosis, secondary hyperparathyroidism, and others. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts have been done on the basis of value (USD).
| By Type | Immediate-release calcifediol | ||
| Extended-release calcifediol | |||
| By Application | Vitamin D Deficiency | ||
| Osteoporosis | |||
| Secondary Hyperparathyroidism | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Calcifediol Supplements Market Research FAQs
How big is the Calcifediol Supplements Market?
The Calcifediol Supplements Market size is expected to reach USD 15.14 billion in 2025 and grow at a CAGR of 9.31% to reach USD 23.63 billion by 2030.
What is the current Calcifediol Supplements Market size?
In 2025, the Calcifediol Supplements Market size is expected to reach USD 15.14 billion.
Who are the key players in Calcifediol Supplements Market?
DSM-Firmenich, Carbogen AMCIS, Chemicea, ApexBio Technology and Midas Pharma are the major companies operating in the Calcifediol Supplements Market.
Which is the fastest growing region in Calcifediol Supplements Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Calcifediol Supplements Market?
In 2025, the North America accounts for the largest market share in Calcifediol Supplements Market.
What years does this Calcifediol Supplements Market cover, and what was the market size in 2024?
In 2024, the Calcifediol Supplements Market size was estimated at USD 13.73 billion. The report covers the Calcifediol Supplements Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Calcifediol Supplements Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Calcifediol Supplements Industry Report
Statistics for the 2025 Calcifediol Supplements market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Calcifediol Supplements analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
